Shanghai Pharmaceuticals Holding Co Ltd (601607) - Net Assets

Latest as of March 2026: CN¥91.47 Billion CNY ≈ $13.38 Billion USD

Based on the latest financial reports, Shanghai Pharmaceuticals Holding Co Ltd (601607) has net assets worth CN¥91.47 Billion CNY (≈ $13.38 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥235.37 Billion ≈ $34.44 Billion USD) and total liabilities (CN¥143.90 Billion ≈ $21.06 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Shanghai Pharmaceuticals Holding Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥91.47 Billion
% of Total Assets 38.86%
Annual Growth Rate 21.84%
5-Year Change 52.01%
10-Year Change 143.76%
Growth Volatility 77.48

Shanghai Pharmaceuticals Holding Co Ltd - Net Assets Trend (1994–2025)

This chart illustrates how Shanghai Pharmaceuticals Holding Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Shanghai Pharmaceuticals Holding Co Ltd.

Annual Net Assets for Shanghai Pharmaceuticals Holding Co Ltd (1994–2025)

The table below shows the annual net assets of Shanghai Pharmaceuticals Holding Co Ltd from 1994 to 2025. Also explore Shanghai Pharmaceuticals Holding Co Ltd (601607) net asset momentum to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2025-12-31 CN¥89.79 Billion
≈ $13.14 Billion		 +7.22%
2024-12-31 CN¥83.74 Billion
≈ $12.25 Billion		 +4.25%
2023-12-31 CN¥80.33 Billion
≈ $11.75 Billion		 +2.98%
2022-12-31 CN¥78.00 Billion
≈ $11.41 Billion		 +32.06%
2021-12-31 CN¥59.07 Billion
≈ $8.64 Billion		 +7.90%
2020-12-31 CN¥54.74 Billion
≈ $8.01 Billion		 +10.84%
2019-12-31 CN¥49.39 Billion
≈ $7.23 Billion		 +6.36%
2018-12-31 CN¥46.43 Billion
≈ $6.79 Billion		 +17.03%
2017-12-31 CN¥39.68 Billion
≈ $5.81 Billion		 +7.71%
2016-12-31 CN¥36.83 Billion
≈ $5.39 Billion		 +8.95%
2015-12-31 CN¥33.81 Billion
≈ $4.95 Billion		 +8.71%
2014-12-31 CN¥31.10 Billion
≈ $4.55 Billion		 +7.23%
2013-12-31 CN¥29.00 Billion
≈ $4.24 Billion		 +4.69%
2012-12-31 CN¥27.70 Billion
≈ $4.05 Billion		 +6.62%
2011-12-31 CN¥25.98 Billion
≈ $3.80 Billion		 +118.62%
2010-12-31 CN¥11.88 Billion
≈ $1.74 Billion		 +411.72%
2009-12-31 CN¥2.32 Billion
≈ $339.84 Million		 +11.13%
2008-12-31 CN¥2.09 Billion
≈ $305.80 Million		 +6.71%
2007-12-31 CN¥1.96 Billion
≈ $286.56 Million		 -5.26%
2006-12-31 CN¥2.07 Billion
≈ $302.45 Million		 +3.04%
2005-12-31 CN¥2.01 Billion
≈ $293.52 Million		 -2.68%
2004-12-31 CN¥2.06 Billion
≈ $301.60 Million		 -3.12%
2003-12-31 CN¥2.13 Billion
≈ $311.31 Million		 +6.39%
2002-12-31 CN¥2.00 Billion
≈ $292.60 Million		 +9.98%
2001-12-31 CN¥1.82 Billion
≈ $266.06 Million		 +84.53%
2000-12-31 CN¥985.30 Million
≈ $144.18 Million		 +15.93%
1999-12-31 CN¥849.92 Million
≈ $124.37 Million		 +19.13%
1998-12-31 CN¥713.42 Million
≈ $104.40 Million		 +149.80%
1997-12-31 CN¥285.60 Million
≈ $41.79 Million		 +51.01%
1996-12-31 CN¥189.12 Million
≈ $27.67 Million		 +3.37%
1995-12-31 CN¥182.95 Million
≈ $26.77 Million		 -6.94%
1994-12-31 CN¥196.60 Million
≈ $28.77 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Shanghai Pharmaceuticals Holding Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 246999.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings CN¥40.72 Billion 53.66%
Other Components CN¥35.17 Billion 46.34%
Total Equity CN¥75.89 Billion 100.00%

Shanghai Pharmaceuticals Holding Co Ltd Competitors by Market Cap

The table below lists competitors of Shanghai Pharmaceuticals Holding Co Ltd ranked by their market capitalization.

Company Market Cap
Bank of Maharashtra
NSE:MAHABANK
 $6.62 Billion
Schaeffler India Limited
NSE:SCHAEFFLER
 $6.62 Billion
99 Speed Mart Retail Holdings Berhad
KLSE:5326
 $6.62 Billion
KION GROUP AG ADRS/1/4
F:KGX1
 $6.62 Billion
CSN Mineração S.A
SA:CMIN3
 $6.61 Billion
Prestige Estates Projects Limited
NSE:PRESTIGE
 $6.60 Billion
JCHX Mining Management Co Ltd
SHG:603979
 $6.60 Billion
Albertsons Companies
NYSE:ACI
 $6.60 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shanghai Pharmaceuticals Holding Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 71,675,620,000 to 75,891,327,824, a change of 4,215,707,824 (5.9%).
  • Net income of 5,724,557,508 contributed positively to equity growth.
  • Dividend payments of 2,799,950,877 reduced retained earnings.
  • Other factors increased equity by 1,291,101,193.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CN¥5.72 Billion +7.54%
Dividends Paid CN¥2.80 Billion -3.69%
Other Changes CN¥1.29 Billion +1.7%
Total Change CN¥- 5.88%

Book Value vs Market Value Analysis

This analysis compares Shanghai Pharmaceuticals Holding Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.79x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 40.19x to 0.79x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1994-12-31 CN¥0.40 CN¥16.21 x
1995-12-31 CN¥0.38 CN¥16.21 x
1996-12-31 CN¥0.39 CN¥16.21 x
1997-12-31 CN¥0.59 CN¥16.21 x
1998-12-31 CN¥1.23 CN¥16.21 x
1999-12-31 CN¥1.29 CN¥16.21 x
2000-12-31 CN¥1.63 CN¥16.21 x
2001-12-31 CN¥3.09 CN¥16.21 x
2002-12-31 CN¥3.20 CN¥16.21 x
2003-12-31 CN¥3.55 CN¥16.21 x
2004-12-31 CN¥3.62 CN¥16.21 x
2005-12-31 CN¥3.61 CN¥16.21 x
2006-12-31 CN¥3.60 CN¥16.21 x
2007-12-31 CN¥2.87 CN¥16.21 x
2008-12-31 CN¥2.97 CN¥16.21 x
2009-12-31 CN¥0.92 CN¥16.21 x
2010-12-31 CN¥4.58 CN¥16.21 x
2011-12-31 CN¥9.53 CN¥16.21 x
2012-12-31 CN¥9.16 CN¥16.21 x
2013-12-31 CN¥9.65 CN¥16.21 x
2014-12-31 CN¥10.35 CN¥16.21 x
2015-12-31 CN¥11.13 CN¥16.21 x
2016-12-31 CN¥11.76 CN¥16.21 x
2017-12-31 CN¥12.66 CN¥16.21 x
2018-12-31 CN¥13.77 CN¥16.21 x
2019-12-31 CN¥14.66 CN¥16.21 x
2020-12-31 CN¥15.96 CN¥16.21 x
2021-12-31 CN¥17.37 CN¥16.21 x
2022-12-31 CN¥19.26 CN¥16.21 x
2023-12-31 CN¥18.51 CN¥16.21 x
2024-12-31 CN¥19.35 CN¥16.21 x
2025-12-31 CN¥20.46 CN¥16.21 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shanghai Pharmaceuticals Holding Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 7.54%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 2.02%
  • • Asset Turnover: 1.22x
  • • Equity Multiplier: 3.07x
  • Recent ROE (7.54%) is below the historical average (9.22%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1994 10.48% 8.54% 0.57x 2.15x CN¥940.26K
1995 10.03% 5.44% 0.75x 2.46x CN¥52.68K
1996 8.04% 4.74% 0.64x 2.65x CN¥-3.70 Million
1997 10.04% 8.44% 0.57x 2.07x CN¥126.97K
1998 13.17% 1.78% 1.69x 4.37x CN¥18.94 Million
1999 15.04% 2.08% 1.48x 4.87x CN¥31.65 Million
2000 23.28% 4.02% 1.30x 4.45x CN¥105.43 Million
2001 9.65% 2.79% 1.21x 2.85x CN¥-5.25 Million
2002 8.07% 1.74% 1.34x 3.46x CN¥-30.11 Million
2003 8.93% 1.58% 1.59x 3.56x CN¥-18.53 Million
2004 5.28% 0.86% 1.67x 3.67x CN¥-83.19 Million
2005 2.87% 0.47% 1.68x 3.63x CN¥-125.23 Million
2006 3.91% 0.60% 1.71x 3.80x CN¥-106.84 Million
2007 4.04% 0.48% 1.95x 4.34x CN¥-97.86 Million
2008 4.85% 0.50% 2.13x 4.59x CN¥-86.92 Million
2009 9.45% 0.89% 2.26x 4.72x CN¥-10.02 Million
2010 14.98% 3.66% 1.33x 3.08x CN¥454.80 Million
2011 8.85% 3.72% 1.15x 2.07x CN¥-265.61 Million
2012 8.33% 3.02% 1.33x 2.07x CN¥-411.06 Million
2013 8.53% 2.83% 1.39x 2.17x CN¥-381.80 Million
2014 9.31% 2.80% 1.44x 2.31x CN¥-191.08 Million
2015 9.61% 2.73% 1.42x 2.48x CN¥-116.04 Million
2016 10.11% 2.65% 1.46x 2.62x CN¥34.14 Million
2017 10.35% 2.69% 1.39x 2.77x CN¥117.56 Million
2018 9.95% 2.44% 1.25x 3.25x CN¥-20.29 Million
2019 9.80% 2.19% 1.36x 3.29x CN¥-84.91 Million
2020 9.91% 2.34% 1.29x 3.29x CN¥-39.25 Million
2021 10.32% 2.36% 1.32x 3.31x CN¥157.52 Million
2022 8.38% 2.42% 1.17x 2.95x CN¥-1.09 Billion
2023 5.50% 1.45% 1.23x 3.09x CN¥-3.08 Billion
2024 6.35% 1.65% 1.24x 3.09x CN¥-2.62 Billion
2025 7.54% 2.02% 1.22x 3.07x CN¥-1.86 Billion

Industry Comparison

This section compares Shanghai Pharmaceuticals Holding Co Ltd's net assets metrics with peer companies in the Medical Distribution industry.

Industry Context

  • Industry: Medical Distribution
  • Average net assets among peers: $8,685,482,554
  • Average return on equity (ROE) among peers: 11.50%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Shanghai Pharmaceuticals Holding Co Ltd (601607) CN¥91.47 Billion 10.48% 1.57x $6.62 Billion
China National Accord Medicines Corp Ltd (000028) $357.13 Million 11.35% 0.25x $1.41 Billion
Shenzhen Glory Medical Co Ltd (002551) $1.46 Billion 7.01% 0.62x $394.67 Million
Shandong Realcan Pharmaceutical Co Ltd (002589) $1.83 Billion 9.92% 2.11x $647.35 Million
China National Accord Medicines Corp Ltd (200028) $4.85 Billion 13.45% 1.64x $120.33 Million
Qingdao Baheal Medical INC. (301015) $1.08 Billion 23.79% 1.42x $1.81 Billion
China Meheco Co Ltd (600056) $1.54 Billion 15.23% 0.77x $1.94 Billion
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) $41.12 Billion 7.25% 1.05x $4.03 Billion
China National Medicines Corp Ltd (600511) $10.61 Billion 13.23% 1.03x $2.90 Billion
Liaoning Cheng Da Co Ltd (600739) $20.00 Billion 4.74% 0.66x $2.30 Billion
Jointown Pharmaceutical Group Co Ltd (600998) $4.00 Billion 8.99% 1.03x $3.70 Billion

About Shanghai Pharmaceuticals Holding Co Ltd

SHG:601607 China Medical Distribution
Market Cap
$6.62 Billion
CN¥45.21 Billion CNY
Market Cap Rank
#2980 Global
#372 in China
Share Price
CN¥16.21
Change (1 day)
-0.86%
52-Week Range
CN¥15.29 - CN¥18.41
All Time High
CN¥25.03
Categories
Companies in China Medical Distribution
About

Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric … Read more